Extended-interval dosing of tobramycin in neonates: Implications for therapeutic drug monitoring

Clinical Pharmacology and Therapeutics

Volumn 71, Issue 5, 2002, Pages 349-358

  de Hoog, Matthijs ^a,b,c,d,e   Mouton, Johan W ^a,b,c,d,e   Schoemaker, Rik C ^a,b,c,d,e   Verduin, Cees M ^a,b,c,d,e   van den Anker, John N ^a,b,c,d,e  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d The Heart Center   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOBRAMYCIN;

APGAR SCORE; ARTICLE; BIRTH WEIGHT; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG MONITORING; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN SEPSIS; POPULATION MODEL; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FORECASTING; HUMANS; INFANT, NEWBORN; LINEAR MODELS; TOBRAMYCIN;

EID: 0036097333     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.123595     Document Type: Article

References (48)

1. The global impact of neonatal infection
2. Decline in sepsis-associated neonatal and infant deaths in the United States, 1979 trough 1994
3. Early onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network
4. Increasing incidence of gram-negative rod bacteremia in a newborn intensive care unit
5. Diagnosis of neonatal bacterial infection: Hematologic and pathologic findings in fatal and nonfatal cases
6. Volume of blood required to detect common neonatal pathogens
7. A comparison of ceftazidime and aminoglycoside based regimens as empirical treatment in 1316 cases of suspected sepsis in the newborn
8. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
9. Tobramycin population pharmacokinetics in neonates
10. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses
11. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy
12. Once-daily gentamicin dosing in newborn infants
13. Population pharmacokinetics of gentamicin in preterm neonates: Evaluation of a once-daily dosage regimen
14. Failure of AUC to predict correct dosing adjustments for once daily aminoglycosides
15. Clinical assessment of gestational age in the newborn infant
16. Some suggestions for measuring predictive performance
17. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides
18. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides
19. Single or multiple daily doses of aminoglycosides: A meta analysis
20. Experience with a once-daily aminoglycoside program administered to 2184 adult patients
21. Once daily aminoglycoside dosing in full term neonates
22. Once-a-day administration of amikacin in neonates: Assessment of nephrotoxicity and ototoxicity
23. Predictors of trough serum gentamicin concentrations in neonates
24. Pharmacokinetics and antibacterial activity of daily gentamicin
25. Tobramycin pharmacokinetics in premature identical twins during newborn period
26. Time course of trough serum gentamicin concentrations in preterm and term neonates
27. Evaluation of bayesian forecasting for individualized gentamicin dosage in infants weighing 1000 g or less
28. Gentamicin kinetics in the neonate
29. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia
30. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis
31. Gentamicin blood levels: A guide to nephrotoxicity
32. Prospective comparative study of variable dosage and variable frequency regimens for administration of gentamicin
33. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance
34. Practicalities of once-daily aminoglycoside dosing
35. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve
36. Once versus thrice daily gentamicin in patients with serious infections
37. A suggested approach to once-daily aminoglycoside dosing
38. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens
39. Prediction of gentamicin concentrations in neonates and infants using a Bayesian pharmacokinetic model
40. The predictive performance of therapeutic drug monitoring (TDM) of amikacin in neonates using an early single determination of the serum concentration together with a population model
41. Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method
42. Population pharmacokinetics of gentamicin in neonates
43. Gentamicin monitoring in neonates
44. Nonoliguric and oliguric acute renal failure in asphyxiated term neonates
45. Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant
46. Ceftazidime pharmacokinetics in preterm infants: Effect of postnatal age and postnatal exposure to indomethacin
47. A critical reevaluation of the "therapeutic range" of aminoglycosides